Adbry Injection, Solution
NDC 50222-346
View dosage, usage, ingredients, routes, and UNII mappings.
Product Information
Adbry (tralokinumab-ldrm) is a BLA-approved product labeled by Leo Pharma Inc.. This medication is typically used as a interleukin-13 antagonist [epc]. It is supplied as a injection, solution for subcutaneous administration. This product entry covers the primary NDC 50222-346 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
50222-346
Proprietary Name:
Adbry
Non-Proprietary Name: [1]
Tralokinumab-ldrm
Substance Name: [2]
Tralokinumab
NDC Directory Status:
Human Prescription Drug
Product Type: [3]
ACTIVE PRODUCT INCLUDED in the NDC Directory
Code Navigator:
Clinical Specifications
Dosage Form:
Injection, Solution
- A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route(s): [4]
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
50222
Product Label ID:
FDA Application Number: [6]
BLA761180
Marketing Category: [8]
BLA - A product marketed under an approved Biologic License Application.
Marketing Timeline
Start Marketing Date: [9]
01-02-2022
Listing Expiration Date: [11]
12-31-2026
Exclude Flag: [12]
N
Code Structure Chart
Product Details
What is NDC 50222-346?
The NDC code 50222-346 is assigned by the FDA to the product Adbry. It is commonly known by its generic name, tralokinumab-ldrm. This pharmaceutical product is labeled by Leo Pharma Inc. and is currently categorized as listed product. The medication is a injection, solution administered via subcutaneous route. In terms of distribution, this product is available in 3 different package configurations. The associated package NDC(s) include: 50222-346-02, 50222-346-04, 50222-346-92. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.
What are Active Ingredients of this product?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
- TRALOKINUMAB 150 mg/mL - a potent and selective IL-13-neutralizing IgG4 mAb
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TRALOKINUMAB (UNII: GK1LYB375A)
- TRALOKINUMAB (UNII: GK1LYB375A) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ACETIC ACID (UNII: Q40Q9N063P)
- POLYSORBATE 80 (UNII: 6OZP39ZG8H)
- SODIUM ACETATE (UNII: 4550K0SC9B)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 2589378 - tralokinumab-ldrm 150 MG in 1 ML Prefilled Syringe
- RxCUI: 2589378 - 1 ML tralokinumab-ldrm 150 MG/ML Prefilled Syringe
- RxCUI: 2589378 - tralokinumab-ldrm 150 MG per 1 ML Prefilled Syringe
- RxCUI: 2589378 - tralokinumab-ldrm 150 MG/ML per 1 ML Prefilled Syringe
- RxCUI: 2589384 - Adbry 150 MG/ML in 1 ML Prefilled Syringe
Which are the Pharmacologic Classes of this product?
A pharmacologic class is a group of drugs that share the same scientifically documented properties. The following is a list of the reported pharmacologic class(es) corresponding to the active ingredients of this product.
* Please review the full disclaimer at the bottom of this page.
Patient Education
Tralokinumab-ldrm injection
Tralokinumab injection is used to treat moderate to severe eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults who cannot use topical medications for their condition or whose eczema has not responded to topical medications. Tralokinumab is in a class of medications called interleukin-13 receptor inhibitors. It works by blocking the activity of interleukin-13, a substance in the body that causes inflammation.
[Learn More]
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Non-Proprietary Name? The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
What is the Substance Name? An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
What kind of product is this? Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
What are the Administration Routes? The translation of the route code submitted by the firm, indicating route of administration.
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".
